Two Reliable Methodical Approaches for Non-Invasive RHD Genotyping of a Fetus from Maternal Plasma
Authors:
- Jana BohmovaJBJana Bohmova
- Marek LubuskyMLMarek Lubusky
- Iva HoluskovaIHIva Holuskova
- Martina StudnickovaMSMartina Studnickova
- Romana KratochvilovaRKRomana Kratochvilova
- Eva KrejcirikovaEKEva Krejcirikova
- Veronika DurdovaVDVeronika Durdova
- Tereza KratochvilovaTKTereza Kratochvilova
- Ladislav DusekLDLadislav Dusek
- Martin ProchazkaMPMartin Prochazka
- Radek VodickaRVRadek Vodicka
Open Access
- 5 August 2020
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 10 (8) , 564
Abstract
Noninvasive fetal RHD genotyping is an important tool for predicting RhD incompatibility between a pregnant woman and a fetus. This study aimed to assess a methodological approach other than the commonly used one for noninvasive fetal RHD genotyping on a representative set of RhD-negative pregnant women. The methodology must be accurate, reliable, and broadly available for implementation into routine clinical practice. A total of 337 RhD-negative pregnant women from the Czech Republic region were tested in this study. The fetal RHD genotype was assessed using two methods: real-time PCR and endpoint quantitative fluorescent (QF) PCR. We used exon-7-specific primers from the RHD gene, along with internal controls. Plasma samples were analyzed and measured in four/two parallel reactions to determine the accuracy of the RHD genotyping. The RHD genotype was verified using DNA analysis from a newborn buccal swab. Both methods showed an excellent ability to predict the RHD genotype. Real-time PCR achieved its greatest accuracy of 98.6% (97.1% sensitivity and 100% specificity (95% CI)) if all four PCRs were positive/negative. The QF PCR method also achieved its greatest accuracy of 99.4% (100% sensitivity and 98.6% specificity (95% CI)) if all the measurements were positive/negative. Both real-time PCR and QF PCR were reliable methods for precisely assessing the fetal RHD allele from the plasma of RhD-negative pregnant women.Keywords
Funding Information
- Ministerstvo Zdravotnictví Ceské Republiky (MH CZ – DRO (FNOL, 00098892) 2020)
This publication has 65 references indexed in Scilit:
- Report of the first nationally implemented clinical routine screening for fetal RHD in D− pregnant women to ascertain the requirement for antenatal RhD prophylaxisTransfusion, 2011
- Implementing Prenatal Diagnosis Based on Cell-Free Fetal DNA: Accurate Identification of Factors Affecting Fetal DNA YieldPLOS ONE, 2011
- Detection of HER2 amplification in circulating free DNA in patients with breast cancerBritish Journal of Cancer, 2011
- Molecular genetics and clinical applications for RHTransfusion and Apheresis Science, 2011
- Molecular determination of RHD zygosity:predicting risk of hemolytic disease of the fetus and newborn related to anti‐DPrenatal Diagnosis, 2010
- Differential methylation of cell‐free circulating DNA among patients with pancreatic cancer versus chronic pancreatitisCancer, 2010
- Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung CancerAnnals of the New York Academy of Sciences, 2008
- Noninvasive fetal RHD genotyping by maternal plasma with capillary electrophoresisTransfusion, 2008
- Refined fluorescent STR quantification of cell‐free fetal DNA during pregnancy in physiological and Down syndrome fetusesPrenatal Diagnosis, 2008
- Methylation status of the fragile histidine triad and E-cadherin genes in plasma of cervical cancer patientsInternational Journal of Gynecological Cancer, 2006